SMS Pharmaceuticals Q2 FY26 Concall Decoded: PAT Pumps 80%, Backward Integration Pays Off π
1. Opening Hook
When pharma giants blame βChina dependence,β SMS Pharma quietly decided to build its own backyard factory. The result? A record-breaking quarter. While others nurse margin blues, SMS turned chemistry into cash flow β no lab coat magic, just solid execution. And if you thought βbackward integrationβ was just corporate jargon, wait till you see how itβs minting margins. Spoiler: this is what happens when your R&D team and your CFO actually talk to each other. Keep reading β it gets spicier than Ibuprofenβs price volatility. π
2. At a Glance
Revenue up 23%: CFO swears itβs demand-driven, not Excel-driven.
EBITDA up 54%: Integration works β like compound interest, but in chemistry.
Margins at 20%: Lab coats and cost controls finally in harmony.
PAT up 80%: Best-ever quarter; investors called it βpharma steroids.β
R&D spend rising: 100 scientists now, planning 200 β scientists are the new salesmen.
Capex βΉ280 Cr: Because expansion is cheaper than excuses.
3. Managementβs Key Commentary
Vamsi Potluri: βOur PAT grew 80% YoY to βΉ25.3 crore β the highest ever.β (Translation: Even the calculator blinked twice before believing this one.)
Vamsi: βBackward integration is central to our strategy.β (Translation: Weβre tired of buying intermediates from China β now weβre our own supplier.)
Vamsi: βInvested βΉ150 crore in-house for intermediates, ensuring cost competitiveness.β (Translation: Spend today, smile tomorrow β also sleep better during global supply shocks.)
Vamsi: βR&D is our strength; 100 scientists at work, 120 DMFs filed.β (Translation: Our R&D lab now looks like a crowded coaching class for molecules.)
Vamsi: βNew βΉ280 crore capex on track; adds capacity and pipeline depth.β (Translation: Managementβs version of saying, βWeβre not done flexing yet.β)
Vamsi: βExpecting 20% growth and 20% EBITDA margins for FY26.β (Translation: Double twenties β sounds like cricket, but feels like chemistry.) βοΈ
4. Numbers Decoded
Metric
Q2 FY26
YoY Growth
Commentary
Revenue
βΉ242.4 Cr
+23%
Broad-based API demand, especially anti-inflammatory & ARV